Unique Wealth LLC Sells 157 Shares of Johnson & Johnson (NYSE:JNJ)

Unique Wealth LLC cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,785 shares of the company’s stock after selling 157 shares during the period. Unique Wealth LLC’s holdings in Johnson & Johnson were worth $837,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. Seven Mile Advisory boosted its holdings in Johnson & Johnson by 1.8% in the 2nd quarter. Seven Mile Advisory now owns 4,841 shares of the company’s stock valued at $708,000 after purchasing an additional 84 shares during the last quarter. Wilkins Investment Counsel Inc. raised its holdings in Johnson & Johnson by 5.6% in the second quarter. Wilkins Investment Counsel Inc. now owns 127,842 shares of the company’s stock valued at $18,685,000 after acquiring an additional 6,768 shares in the last quarter. Rock Point Advisors LLC lifted its position in shares of Johnson & Johnson by 1.2% during the 2nd quarter. Rock Point Advisors LLC now owns 6,103 shares of the company’s stock worth $892,000 after purchasing an additional 70 shares during the last quarter. Providence Wealth Advisors LLC increased its holdings in shares of Johnson & Johnson by 3.2% in the 2nd quarter. Providence Wealth Advisors LLC now owns 9,440 shares of the company’s stock valued at $1,390,000 after acquiring an additional 293 shares during the last quarter. Finally, Stevard LLC increased its stake in Johnson & Johnson by 2.7% in the second quarter. Stevard LLC now owns 3,820 shares of the company’s stock valued at $558,000 after purchasing an additional 100 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the stock in a transaction dated Thursday, December 12th. The stock was bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now directly owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $144.50 on Tuesday. The business’s 50 day moving average is $149.39 and its 200-day moving average is $156.10. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $347.90 billion, a PE ratio of 20.91, a PEG ratio of 2.52 and a beta of 0.51. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping the consensus estimate of $2.21 by $0.21. The business had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. Johnson & Johnson’s revenue was up 5.2% on a year-over-year basis. During the same quarter last year, the company earned $2.66 EPS. Sell-side analysts predict that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.43%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 71.78%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on JNJ shares. Wells Fargo & Company boosted their target price on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 16th. Morgan Stanley raised their target price on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Bank of America reissued a “neutral” rating and issued a $166.00 target price on shares of Johnson & Johnson in a research report on Tuesday, December 10th. Finally, Guggenheim boosted their target price on Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. Seven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $174.71.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.